Drug Interactions between clonazepam and Mepron
This report displays the potential drug interactions for the following 2 drugs:
- clonazepam
- Mepron (atovaquone)
Interactions between your drugs
No interactions were found between clonazepam and Mepron. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
clonazepam
A total of 532 drugs are known to interact with clonazepam.
- Clonazepam is in the following drug classes: benzodiazepine anticonvulsants, benzodiazepines.
-
Clonazepam is used to treat the following conditions:
- Anxiety (off-label)
- Benzodiazepine Withdrawal (off-label)
- Bipolar Disorder (off-label)
- Borderline Personality Disorder (off-label)
- Burning Mouth Syndrome (off-label)
- Chronic Myofascial Pain (off-label)
- Cluster-Tic Syndrome (off-label)
- Epilepsy
- Hyperekplexia (off-label)
- Insomnia (off-label)
- Lennox-Gastaut Syndrome
- Meniere's Disease
- Migraine Prevention (off-label)
- Night Terrors (off-label)
- Obsessive Compulsive Disorder (off-label)
- Panic Disorder
- Periodic Limb Movement Disorder (off-label)
- Primary Orthostatic Tremor (off-label)
- Restless Legs Syndrome (off-label)
- Seizure Prevention
- Seizures
- Sleep Paralysis (off-label)
- Temporomandibular Joint Disorder (off-label)
Mepron
A total of 92 drugs are known to interact with Mepron.
- Mepron is in the drug class miscellaneous antibiotics.
- Mepron is used to treat the following conditions:
Drug and food interactions
atovaquone food
Applies to: Mepron (atovaquone)
ADJUST DOSING INTERVAL: Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone. In 16 healthy volunteers, administration of a single 750 mg dose of atovaquone suspension following a standard breakfast (23 g fat: 610 kCal) resulted in an approximately 3.4-fold increase in the mean peak plasma concentration (Cmax) and a 2.5-fold increase in the mean area under the plasma concentration-time curve (AUC) of atovaquone compared to administration following an overnight fast. In a study consisting of 19 HIV-infected volunteers receiving atovaquone suspension 500 mg/day, Cmax and AUC of atovaquone increased by 72% and 66%, respectively, in the fed state relative to the fasting state.
MANAGEMENT: To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day. Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
clonazePAM food
Applies to: clonazepam
GENERALLY AVOID: Acute ethanol ingestion may potentiate the CNS effects of many benzodiazepines. Tolerance may develop with chronic ethanol use. The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition. Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.
MANAGEMENT: Patients should be advised to avoid alcohol during benzodiazepine therapy.
References (7)
- MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM (1977) "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol, 11, p. 345-9
- Whiting B, Lawrence JR, Skellern GG, Meier J (1979) "Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide." Br J Clin Pharmacol, 7, p. 95-100
- Divoll M, Greenblatt DJ, Lacasse Y, Shader RI (1981) "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl), 73, p. 381-3
- Juhl RP, Van Thiel DH, Dittert LW, Smith RB (1984) "Alprazolam pharmacokinetics in alcoholic liver disease." J Clin Pharmacol, 24, p. 113-9
- Ochs HR, Greenblatt DJ, Arendt RM, Hubbel W, Shader RI (1984) "Pharmacokinetic noninteraction of triazolam and ethanol." J Clin Psychopharmacol, 4, p. 106-7
- Staak M, Raff G, Nusser W (1979) "Pharmacopsychological investigations concerning the combined effects of dipotassium clorazepate and ethanol." Int J Clin Pharmacol Biopharm, 17, p. 205-12
- Nichols JM, Martin F, Kirkby KC (1993) "A comparison of the effect of lorazepam on memory in heavy and low social drinkers." Psychopharmacology (Berl), 112, p. 475-82
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.